Do analysts rate SPRO or GOSS?

Gossamer Bio has a consensus target price of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to SPRO or GOSS?

In the previous week, Spero Therapeutics and Spero Therapeutics both had 2 articles in the media. Spero Therapeutics' average media sentiment score of 1.42 beat Gossamer Bio's score of 0.93 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CNTX or GOSS?

In the previous week, Context Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Gossamer Bio. Context Therapeutics' average media sentiment score of 0.93 equaled Gossamer Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GOSS or IPHA?

Innate Pharma has lower revenue, but higher earnings than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.85 -$170.37M -$0.79 N/A Innate Pharma $10.19M 16.28 -$55.64M N/A N/A

Is GOSS or IPHA more profitable?

Innate Pharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% Innate Pharma N/A N/A N/A

Do analysts prefer CNTN or GOSS?

Gossamer Bio has a consensus target price of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media prefer PRQR or GOSS?

In the previous week, ProQR Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for ProQR Therapeutics and 2 mentions for Gossamer Bio. ProQR Therapeutics' average media sentiment score of 1.23 beat Gossamer Bio's score of 0.93 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gossamer Bio (GOSS) Competitors

$0.18 +0.01 (+8.09%)

As of 10:45 AM Eastern

Compare

GOSS vs. SPRO, CNTX, IPHA, CNTN, and PRQR

Should you buy Gossamer Bio stock or one of its competitors? MarketBeat compares Gossamer Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gossamer Bio include Spero Therapeutics (SPRO), Context Therapeutics (CNTX), Innate Pharma (IPHA), Hillstream Biopharma (CNTN), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

How does Gossamer Bio compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Spero Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Gossamer Bio's net margin of -324.82%. Spero Therapeutics' return on equity of 35.58% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Gossamer Bio	-324.82%	N/A	-96.10%

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.54	$8.57M	$0.24	12.23
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A

Gossamer Bio has a consensus target price of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Spero Therapeutics and Spero Therapeutics both had 2 articles in the media. Spero Therapeutics' average media sentiment score of 1.42 beat Gossamer Bio's score of 0.93 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spero Therapeutics beats Gossamer Bio on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Context Therapeutics currently has a consensus price target of $6.60, indicating a potential upside of 867.74%. Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Context Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Context Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Gossamer Bio. Context Therapeutics' average media sentiment score of 0.93 equaled Gossamer Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Gossamer Bio	-324.82%	N/A	-96.10%

Context Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Context Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A

Summary

Context Therapeutics beats Gossamer Bio on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Innate Pharma?

Gossamer Bio (NASDAQ:GOSS) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Gossamer Bio had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Gossamer Bio and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Gossamer Bio's score of 0.93 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Gossamer Bio	Positive
Innate Pharma	Very Positive

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gossamer Bio presently has a consensus target price of $5.00, indicating a potential upside of 2,757.14%. Innate Pharma has a consensus target price of $5.00, indicating a potential upside of 183.13%. Given Gossamer Bio's higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Innate Pharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Innate Pharma	N/A	N/A	N/A

Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Innate Pharma has lower revenue, but higher earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A
Innate Pharma	$10.19M	16.28	-$55.64M	N/A	N/A

Summary

Innate Pharma beats Gossamer Bio on 8 of the 14 factors compared between the two stocks.

How does Gossamer Bio compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Hillstream Biopharma has higher earnings, but lower revenue than Gossamer Bio. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A

In the previous week, Gossamer Bio had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Gossamer Bio and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Gossamer Bio's score of 0.93 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Gossamer Bio	Positive

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hillstream Biopharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Hillstream Biopharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Gossamer Bio	-324.82%	N/A	-96.10%

Summary

Gossamer Bio beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Gossamer Bio has a net margin of -324.82% compared to ProQR Therapeutics' net margin of -331.33%. Gossamer Bio's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Gossamer Bio	-324.82%	N/A	-96.10%

ProQR Therapeutics has higher earnings, but lower revenue than Gossamer Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.70	-$47.73M	-$0.50	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A

ProQR Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 388.22%. Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for ProQR Therapeutics and 2 mentions for Gossamer Bio. ProQR Therapeutics' average media sentiment score of 1.23 beat Gossamer Bio's score of 0.93 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ProQR Therapeutics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.07M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.22	20.05	24.05	24.76
Price / Sales	0.85	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-0.33	8.16	10.69	6.90
Net Income	-$170.37M	$23.89M	$3.57B	$337.45M
7 Day Performance	5.68%	3.66%	1.56%	2.84%
1 Month Performance	-48.53%	1.69%	2.49%	4.78%
1 Year Performance	-85.89%	46.95%	26.51%	33.08%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.3495 of 5 stars	$0.18 +8.1%	$5.00 +2,757.1%	-86.9%	$41.07M	$48.47M	N/A	180	Gap Up
SPRO Spero Therapeutics	1.6515 of 5 stars	$2.74 -2.8%	N/A	+0.7%	$163.28M	$66.80M	11.42	150	Positive News
CNTX Context Therapeutics	3.1597 of 5 stars	$1.71 -2.3%	$6.60 +286.0%	+120.8%	$160.79M	N/A	N/A	7
IPHA Innate Pharma	3.2999 of 5 stars	$1.76 +2.9%	$5.00 +184.1%	-7.1%	$160.61M	$10.19M	N/A	220
CNTN Hillstream Biopharma	0.9347 of 5 stars	$2.65 +15.2%	N/A	N/A	$160.55M	N/A	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. SPRO, CNTX, IPHA, CNTN, and PRQR

How does Gossamer Bio compare to Spero Therapeutics?

Summary

How does Gossamer Bio compare to Context Therapeutics?

Summary

How does Gossamer Bio compare to Innate Pharma?

Summary

How does Gossamer Bio compare to Hillstream Biopharma?

Summary

How does Gossamer Bio compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. SPRO, CNTX, IPHA, CNTN, and PRQR

How does Gossamer Bio compare to Spero Therapeutics?

Which has more volatility and risk, SPRO or GOSS?

Is SPRO or GOSS more profitable?

Do institutionals and insiders hold more shares of SPRO or GOSS?

Which has stronger valuation & earnings, SPRO or GOSS?

Do analysts rate SPRO or GOSS?

Does the media refer more to SPRO or GOSS?

Summary

How does Gossamer Bio compare to Context Therapeutics?

Do analysts recommend CNTX or GOSS?

Do institutionals & insiders believe in CNTX or GOSS?

Which has more risk and volatility, CNTX or GOSS?

Does the media prefer CNTX or GOSS?

Is CNTX or GOSS more profitable?

Which has higher earnings & valuation, CNTX or GOSS?

Summary

How does Gossamer Bio compare to Innate Pharma?

Does the media favor GOSS or IPHA?

Do insiders & institutionals believe in GOSS or IPHA?

Do analysts recommend GOSS or IPHA?

Is GOSS or IPHA more profitable?

Which has more risk & volatility, GOSS or IPHA?

Which has preferable earnings and valuation, GOSS or IPHA?

Summary

How does Gossamer Bio compare to Hillstream Biopharma?

Do analysts prefer CNTN or GOSS?

Which has higher earnings and valuation, CNTN or GOSS?

Does the media refer more to CNTN or GOSS?

Do insiders and institutionals hold more shares of CNTN or GOSS?

Which has more volatility & risk, CNTN or GOSS?

Is CNTN or GOSS more profitable?

Summary

How does Gossamer Bio compare to ProQR Therapeutics?

Which has more volatility and risk, PRQR or GOSS?

Is PRQR or GOSS more profitable?

Which has preferable valuation and earnings, PRQR or GOSS?

Do analysts prefer PRQR or GOSS?

Do insiders & institutionals hold more shares of PRQR or GOSS?

Does the media prefer PRQR or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools